Alendronic acid
Based on 10 publication(s) in Google Scholar
Alendronate acid is an orally active bisphosphonate which binds to bone surfaces and inhibits bone resorption by osteoclasts. Alendronate acid induces skeletal alterations in the chicken embryonic development model. Alendronate acid can be used for osteoporosis research.
For research use only. We do not sell to patients.
- Purity: 98.0%
- CAS No.: 66376-36-1
- Formula: C4H13NO7P2
- Molecular Weight:249.10
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
NF-κB Signaling Compound Library
HY-L014
-
Stem Cell Signaling Compound Library
HY-L017
-
FDA-Approved Drug Library
HY-L022
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Antioxidant Compound Library
HY-L037
-
Oxygen Sensing Compound Library
HY-L045
-
Pyroptosis Compound Library
HY-L059
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Angiogenesis-Related Compound Library
HY-L088
-
Transcription Factor-Targeted Library
HY-L090
-
Food-Sourced Compound Library
HY-L094
-
Targeted Diversity Library
HY-L099
-
Rare Diseases Drug Library
HY-L102
-
EMA-Approved Drug Library
HY-L116
-
Human Metabolite Library
HY-L123
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Pain-Related Compound Library
HY-L139
-
Off-patent Drug Library
HY-L141
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Nephrotoxicity Compound Library
HY-L229
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) Alendronic acid
More- J Pharm Anal. 2025 Jul 31.
- Cell Rep. 2022 Oct 25;41(4):111508. [Abstract]
- J Med Chem. 2024 Sep 12;67(17):15738-15755. [Abstract]
- Int J Mol Med. 2025 Dec;56(6):206. [Abstract]
- Biochem Pharmacol. 2025 Aug 13;242(Pt 1):117234. [Abstract]
- Int J Mol Sci. 2024 Jul 16;25(14):7798. [Abstract]
- J Biol Chem. 2019 Jul 19;294(29):11240-11247. [Abstract]
- Bone. 2024 Nov 29:192:117348. [Abstract]
- Pathol Res Pract. 2025 Sep:273:156138. [Abstract]
- Am J Physiol Endocrinol Metab. 2024 May 8. [Abstract]
Customer Validation & Images
-
Bio/Physico-chemical Assay
-
Cell Imaging/Staining
-
Flow Cytometry
-
Flow Cytometry
-
Cell Imaging/Staining
Biological Activity
|
IL-6 |
NF-κB |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BMDM | IC50 |
4.22 μM
Compound: ALN
|
Inhibition of osteoclastogenesis in C57BL/6J mouse Bone marrow macrophage cells assessed as inhibition of RANKL-stimulated osteoclast formation measured after 6 days by tartrate-resistant acid phosphatase (TRAP) staining assay
Inhibition of osteoclastogenesis in C57BL/6J mouse Bone marrow macrophage cells assessed as inhibition of RANKL-stimulated osteoclast formation measured after 6 days by tartrate-resistant acid phosphatase (TRAP) staining assay
|
[PMID: 39185622] |
| HFF | IC50 |
108.8 μM
Compound: 45
|
In vitro inhibitory concentration against the growth of Toxoplasma gondii in human foreskin fibroblast monolayer cells (HFF cells)
In vitro inhibitory concentration against the growth of Toxoplasma gondii in human foreskin fibroblast monolayer cells (HFF cells)
|
[PMID: 15857119] |
| MCF7 | IC50 |
69.5 μM
Compound: Alendronate
|
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 24 to 48 hrs by SRB assay
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 24 to 48 hrs by SRB assay
|
[PMID: 33132173] |
| T-cell | EC50 |
0.9 μM
Compound: Alendronate
|
Effective concentration to activate gammadelta T cells
Effective concentration to activate gammadelta T cells
|
[PMID: 12383012] |
| T-cell | EC50 |
32 μM
Compound: 2
|
Effective concentration against human Gamma delta T cells
Effective concentration against human Gamma delta T cells
|
[PMID: 15828834] |
| T-cell | IC50 |
52 μM
Compound: 32
|
Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using a constrained maximum TNF-alpha release of 2700 pg/mL
Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using a constrained maximum TNF-alpha release of 2700 pg/mL
|
[PMID: 14711309] |
| T-cell | IC50 |
53 μM
Compound: 32
|
Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using individual observed maximum TNF-alpha release
Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using individual observed maximum TNF-alpha release
|
[PMID: 14711309] |
| Vero | IC50 |
25 μM
Compound: 1
|
Inhibition of Trypanosoma cruzi Amastigotes was determined in Vero cells culture and fetal calf serum
Inhibition of Trypanosoma cruzi Amastigotes was determined in Vero cells culture and fetal calf serum
|
[PMID: 11300872] |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Viable fertilized chick eggs (7 days)[3]
-
Dosage:1.5E-7 M, 1.5E-8 M, 1.5E-9 M, and 1.5E-10 M
-
Administration:intra-air cell injection, single dose at embryonic day 7, exposure for 4 days
-
Result:Showed an 87.5% viability rate and a 75% viability rate at 1.5E-10 M and other doses, respectively.
Significantly reduced bone morphometric indexes (bone volume (BV) and bone surface (BS)) and cortical thickness in a dose-dependent manner.
Significantly reduced dimensions and diminished mineralization in a concentration-dependent manner.
Significantly increased TNFRSF11B, NF-κB1 and IL-6 levels, and decreased TNFRSF11A, CTSK, COL1A2, SPP1, and SOST levels, compared to control.
Chemical Information
-
CAS No. 66376-36-1
-
Appearance Solid
-
Molecular Weight 249.10
-
Formula C4H13NO7P2
-
Color White to off-white
-
SMILES
OC(P(O)(O)=O)(CCCN)P(O)(O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
-
Cell Rep
Genome-wide CRISPR screen reveals v-ATPase as a drug target to lower levels of ALS protein ataxin-2. [Abstract]2022 Oct 25;41(4):111508. PMID: 36288714 -
J Med Chem
Discovery of Novel Neo-Clerodane Derivatives as Potent Dual-Functional Antiosteoporosis Agents through Targeting Peroxisome Proliferator-Activated Receptor-γ. [Abstract]2024 Sep 12;67(17):15738-15755. PMID: 39185622
Alendronic acid purchased from MedChemExpress. Usage Cited in: J Med Chem. 2024 Sep 12;67(17):15738-15755. [Abstract]
Alendronate sodium hydrate (33 μM; 48 h) significantly restored mpx expression in Tg(drl:hoxa9) embryos.
Alendronic acid purchased from MedChemExpress. Usage Cited in: J Med Chem. 2024 Sep 12;67(17):15738-15755. [Abstract]
Alendronate sodium hydrate (33 μM; 48 h) recovered macrophage differentiation in Tg(drl:hoxa9) embryos.
Alendronic acid purchased from MedChemExpress. Usage Cited in: J Med Chem. 2024 Sep 12;67(17):15738-15755. [Abstract]
Flow cytometry analysis of CD14 and CD11b expression in U937 cells treated with different doses of Alendronate sodium hydrate (20-40 μM).
Alendronic acid purchased from MedChemExpress. Usage Cited in: J Med Chem. 2024 Sep 12;67(17):15738-15755. [Abstract]
Flow cytometry analysis of CD14 and CD11b expression in U937 cells treated with Alendronate sodium hydrate (30 μM; 3 d).
Alendronic acid purchased from MedChemExpress. Usage Cited in: J Med Chem. 2024 Sep 12;67(17):15738-15755. [Abstract]
Alendronate sodium hydrate (30 μM) induced chromatin condensation and increased the nucleocytoplasmic ratio in U937 cells, supporting the differentiation of these cells.
-
Int J Mol Med
Cynarin as a potent anti‑osteolytic agent: Targeting MAPK and Nrf2‑Keap1 pathways for osteoclast inhibition and bone protection. [Abstract]2025 Dec;56(6):206. PMID: 40999989 -
Biochem Pharmacol
Irisolidone enhances osteoblast differentiation via the AMPK-ULK1-autophagy Axis to accelerate osteoporotic fracture repair. [Abstract]2025 Aug 13;242(Pt 1):117234. PMID: 40816626 -
Int J Mol Sci
In Vivo Chemical Screening in Zebrafish Embryos Identified FDA-Approved Drugs That Induce Differentiation of Acute Myeloid Leukemia Cells. [Abstract]2024 Jul 16;25(14):7798. PMID: 39063039 -
J Biol Chem
Mature osteoclast-derived apoptotic bodies promote osteogenic differentiation via RANKL-mediated reverse signaling. [Abstract]2019 Jul 19;294(29):11240-11247. PMID: 31167789 -
Bone
2024 Nov 29:192:117348. PMID: 39617111 -
Pathol Res Pract
Alendronate-functionalized ZIF-8 nanoplatform for targeted delivery of SHH siRNA and docetaxel to treat prostate cancer bone metastasis. [Abstract]2025 Sep:273:156138. PMID: 40694986 -
Am J Physiol Endocrinol Metab
Mononuclear phagocyte morphologic response to chemoattractants is dependent on geranylgeranyl pyrophosphate. [Abstract]2024 May 8. PMID: 38717364
Solvent & Solubility
H2O : 3.7 mg/mL (14.85 mM; ultrasonic and warming and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 6.67 mg/mL (26.78 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (476 KB)
- English - EN (476 KB)
- Français - FR (476 KB)
- Deutsch - DE (476 KB)
- Norwegian - NO (476 KB)
- Español - ES (476 KB)
- Swedish - SV (476 KB)
- Italian - IT (476 KB)
- Korean - KR (476 KB)
- Portuguese - PT (476 KB)
-
Handling Instructions (2659 KB)
References
[1]. Imai K. Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation. Clin Interv Aging. 2013;8:681-688. [Content Brief]
[2]. Sharpe M, et al. Alendronate: an update of its use in osteoporosis. Drugs. 2001;61(7):999-1039. [Content Brief]
[3]. de Campos WG, et al. Alendronate induces skeletal alterations in the chicken embryonic development model. Toxicol Appl Pharmacol. 2023 Oct 1;476:116673. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 4.0145 mL | 20.0723 mL | 40.1445 mL | 100.3613 mL |
| 5 mM | 0.8029 mL | 4.0145 mL | 8.0289 mL | 20.0723 mL | |
| 10 mM | 0.4014 mL | 2.0072 mL | 4.0145 mL | 10.0361 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Alendronic acid Related Classifications
HY-B0631 Related Classifications
Powered by Bioz